Orexigen Announces Successful Interim Analysis of Contrave Light Study, Will Resubmit Contrave NDA to FDA

Orexigen Therapeutics (Nasdaq: OREX ) today announced successful results of the interim analysis of the Light Study. Based on these results, the Company will resubmit the Contrave® New Drug Application (NDA) to the United States Food and Drug Administration (FDA) in the next few weeks with potential approval by